Abstract
Abnormalities of coagulation have been reported in patients with thyroid dysfunction, although there is no clear information to explain the mechanism behind such irregularities. We are presenting a case of subclinical hypothyroidism that came with coagulation disturbance (hypocoagulation). Her symptoms resolved with leothyroxin in 4 weeks. Further studies are needed to clear the pathogenesis of the coagulation disturbance in such setting. The article also outlines some patents on hypothyroidism and hyperthyroidism.
Keywords: Hemostasis, hypercoagulability hypocoagulability, subclinical thyroid dysfunction, thyroid dysfunction, hypothyroidism, Graves’ disease, vitamin-mineral complexes, levothyroxine, Willebrand factor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title:Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review
Volume: 6 Issue: 2
Author(s): Parvaneh Ehsanzadeh-Cheemeh, Michelle Thompson and Michal Miller
Affiliation:
Keywords: Hemostasis, hypercoagulability hypocoagulability, subclinical thyroid dysfunction, thyroid dysfunction, hypothyroidism, Graves’ disease, vitamin-mineral complexes, levothyroxine, Willebrand factor
Abstract: Abnormalities of coagulation have been reported in patients with thyroid dysfunction, although there is no clear information to explain the mechanism behind such irregularities. We are presenting a case of subclinical hypothyroidism that came with coagulation disturbance (hypocoagulation). Her symptoms resolved with leothyroxin in 4 weeks. Further studies are needed to clear the pathogenesis of the coagulation disturbance in such setting. The article also outlines some patents on hypothyroidism and hyperthyroidism.
Export Options
About this article
Cite this article as:
Ehsanzadeh-Cheemeh Parvaneh, Thompson Michelle and Miller Michal, Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2012; 6 (2) . https://dx.doi.org/10.2174/187221412800604590
DOI https://dx.doi.org/10.2174/187221412800604590 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry TP73, An Under-Appreciated Player in Non-Hodgkin Lymphoma Pathogenesis and Management
Current Molecular Medicine Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology Nutritional Support in Cancer
Current Nutrition & Food Science Gene Profile Identifies Zinc Transporters Differentially Expressed in Normal Human Organs and Human Pancreatic Cancer
Current Molecular Medicine Thyroid Diseases During Pregnancy: Bibliometric Analysis of Scientific Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Resistance to Anti-VEGF Agents
Current Pharmaceutical Design From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design